After working for years in the pharmaceutical industry, Joseph Dominguez enjoyed the freedom to take on scientific research he found in an academic institution that had no commercial ties. Dominguez finished his Ph.D. earlier this year after studying the role of innate immune cells in early ovarian cancer, which was funded through a federal grant for the past two years. He considered continuing in academia, but will likely return to the private sector in part because of greater scrutiny from the